News of the company SR Pharma - LondonUnited Kingdom

Article 1 to 6 out of 6 concerning SR Pharma plc.

SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry (20 Mar 2007)
SR Pharma plc announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application (IND) for a second siRNA therapeutic which is based on the company 's unique proprietary chemistry. The product is AKIi-5, ...

more information
�
SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD) (07 Feb 2007)
SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary ...

more information
�
SR Pharma Granted Core RNAi Patent by the European Patent Office (08 Jan 2007)
SR Pharma plc announced that the European Patent Office has granted the Company its core RNAi patent EP 03784183.0. This patent covers its novel, stabilised, small interfering RNA (siRNA) molecules with blunt ends and positional modifications. These ...

more information
�
SR Pharma plc Announces Therapeutic Efficacy of Atu027 RNAi in pre-clinical Models of Pancreatic Cancer (01 Dec 2006)
SR Pharma plc announced that studies at the Charit� Hospital have demonstrated the superior therapeutic efficacy of Atu027 RNAi in pre-clinical models of pancreatic cancer when compared to the standard care treatment. The data showed both inhibition ...

more information
�
SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer (15 Sep 2006)
SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charit� Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer ...

more information
�
SR Pharma achieves key technical breakthrough with its lyophilized liposomal-based siRNA formulation (12 Jun 2006)
SR Pharma plc has announced that it has made a technical breakthrough in the formulation of siRNA drugs, that enables its proprietary lyophilized (freeze dried) liposomally formulated siRNA (AtuRNAi) drugs to be stored at room temperature and ...

more information
�

Current News RSS

SR Pharma plc.
London, United Kingdom

Current NewsRSS

SR Pharma plc.London, United Kingdom

Current News RSS

SR Pharma plc.
London, United Kingdom